Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Genetic Technologies; Aushon Biosystems, Phadia

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies this week said that it has created a new North American molecular diagnostics division, which will be led by Lewis Stuart, formerly senior VP of commercial operations at CV Therapeutics. The division will be located in the Eastern US, said Genetic Technologies, and will be responsible for launching the firm's recently acquired BrevaGen test for non-hereditary breast cancer. The BrevaGen test and certain other assets were acquired earlier this year from the now-defunct Perlegen Sciences.

Aushon Biosystems this week said it has placed its 2470 Arrayer with Phadia, an Uppsala, Sweden-based blood diagnostics firm. Phadia's Multiplexing Diagnostics division will use the 2470 in its research efforts to characterize new allergens and to discover biomarker signatures that can be used in the molecular diagnosis of allergies and autoimmune diseases.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.